Olanzapine Therapy in Elderly Patients With Schizophrenia

Sajatovic, Martha; Pérez, Dalia María Aguirre; Brescan, Debra; Ramirez, Luis F.

doi:10.1097/00019442-199911001-00163

Cited by 11 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In open-label trials it has been shown to be well tolerated and causes less extra pyramidal side effects at lower doses, the most common side effects being sedation and orthostatic hypotension (Davidson, Harvey & Vercarcke, 2000;Madhusoondanan, Brecher & Brenner, 1999). Olanzapine has also been shown to reduce positive and negative symptoms in elderly patients with chronic schizophrenia whilst inducing less extra pyramidal symptoms (Barak, Shamir & Zemishlani, 2002;Sajatovic, Perez, Brescan & Ramirez, 1998). Low doses of olanzapine and risperidone can also improve cognitive function in elderly patients with schizophrenia (Harvey, Bertisch & Friedman, 2003).…”

Section: Medicationmentioning

confidence: 99%

Older people with chronic schizophrenia

Karim

Overshott

Burns

2005

Aging & Mental Health

View full text Add to dashboard Cite

Older people with chronic schizophrenia are a numerically small but important group with complex clinical and service needs. Along with a reduction in positive schizophrenic symptoms with increasing age, a majority suffer from negative symptoms, cognitive deficits, depression, side effects due to long-term use of antipsychotics and co-morbid medical problems. They may have social disabilities making them vulnerable to poverty, isolation and poor quality of life. Evidence suggests that judicious use of antipsychotics combined with psychotherapy and psychosocial interventions are effective. There are shortcomings in the standard of both hospital and community care, and the cost implications of providing adequate services are high.

show abstract

Section: Medicationmentioning

confidence: 99%

Older people with chronic schizophrenia

Karim

Overshott

Burns

2005

Aging & Mental Health

View full text Add to dashboard Cite

show abstract

“…Several case reports (Khan and Farver, 2000) and follow-up studies have demontrated the ef®cacy of olanzapine in decreasing the severity of abnormal movements in elderly patients. Sajatovic et al (1998) showed a signi®cant decrease in AIMS scores in elderly patients with schizophrenia (mean age 70.6 years) treated with a mean dose of 8.4 mg of olanzapine. A signi®cant decrease in CGI scores of TD severity was also reported by Madhusoodanan et al (2000) in a prospective study on 11 hospitalized patients aged 60±85 years treated with olanzapine at a dose range of 5±20 mg. A signi®cant decrease in EPS and a substantial stabilization of TD has been reported after 12 months of treatment with risperidone in patients with a median age of 72 years (Davidson et al, 2000).…”

Section: Atypical Antipsychotics and Tdmentioning

confidence: 95%

Tardive dyskinesias in the elderly

Fabbrini

Barbanti

Aurilia

2001

Int. J. Geriat. Psychiatry

View full text Add to dashboard Cite

“…Table 5 [67][68][69][70] shows selected studies of olanzapine in elderly patients with schizophrenia/schizoaffective disorder and Table 6 [48,50,53,71] shows comparison studies of risperidone and olanzapine in elderly patients. Solomons and Geiger [67] conducted a retrospective chart analysis of the efficacy and safety of olanzapine in 58 elderly patients (age range 60-99 years) who had previously failed to respond to other antipsychotic medications.…”

Section: Olanzapinementioning

confidence: 99%

“…In another open-label study, Sajatovic et al [69] assessed the safety and tolerability of olanzapine (mean dose 8.4 mg/day) in 27 elderly patients (mean age 70.6 years, range 65-80 years with schizophrenia. Psychopathology was assessed using the BPRS.…”

Section: Olanzapinementioning

confidence: 99%

The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly

Madhusoodanan

Sinha

Sajatovic

et al. 2006

CDS

Self Cite

View full text Add to dashboard Cite

Schizophrenia and schizoaffective disorder are prevalent in 1% of the adult population. The condition was thought to predominantly affect the young however recent studies have shown that the condition occurs in individuals throughout the life-span. The aim of this review is to discuss the role of atypical antipsychotics in treating schizoaffective disorder and schizophrenia in the elderly. The advent of atypical antipsychotics has made significant strides in the pharmacotherapy of schizophrenia in the elderly. They are as efficacious as conventional agents in reducing the positive symptoms, possibly some what more efficacious in reducing negative symptoms and appear to have a relatively safer adverse effect profile. However metabolic side affects particularly glucose abnormalities and weight gain, cerebrovascular effects, and mortality risk noted in dementia patients are gaining increasing attention. Appropriate monitoring for the metabolic side effects has been recommended by agencies such as the FDA (United States Food and Drug Administration), ADA (American Diabetic Association) and APA (American Psychiatric Association). Treatment of elderly patients is complicated by age related biological factors affecting drug response and presence of comorbid medical conditions and concomitant medication. Current research supports the role of atypical antipsychotics in the treatment of schizophrenia and schizoaffective disorder in the elderly. Despite advantages compared with conventional agents, challenges to successful therapy remain, even with these better tolerated agents.

show abstract

Olanzapine Therapy in Elderly Patients With Schizophrenia

Cited by 11 publications

References 0 publications

Older people with chronic schizophrenia

Older people with chronic schizophrenia

Tardive dyskinesias in the elderly

The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly

Contact Info

Product

Resources

About